Infant Bacterial Therapeutics Stock Market Capitalization
| IBT-B Stock | SEK 39.40 0.60 1.55% |
Infant Bacterial Therapeutics fundamentals help investors to digest information that contributes to Infant Bacterial's financial success or failures. It also enables traders to predict the movement of Infant Stock. The fundamental analysis module provides a way to measure Infant Bacterial's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infant Bacterial stock.
Infant |
Infant Bacterial Therapeutics Company Market Capitalization Analysis
Infant Bacterial's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Infant Bacterial Market Capitalization | 560.25 M |
Most of Infant Bacterial's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infant Bacterial Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Infant Bacterial Therapeutics is about 560.25 M. This is 95.67% lower than that of the Healthcare sector and 88.18% lower than that of the Biotechnology industry. The market capitalization for all Sweden stocks is 97.06% higher than that of the company.
Infant Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infant Bacterial's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infant Bacterial could also be used in its relative valuation, which is a method of valuing Infant Bacterial by comparing valuation metrics of similar companies.Infant Bacterial is currently under evaluation in market capitalization category among its peers.
Infant Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | 271.56 M | |||
| Shares Outstanding | 10.85 M | |||
| Shares Owned By Insiders | 7.23 % | |||
| Shares Owned By Institutions | 33.28 % | |||
| Price To Earning | (18.41) X | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 8,324 X | |||
| Gross Profit | 12 K | |||
| EBITDA | (43.76 M) | |||
| Net Income | (44.99 M) | |||
| Cash And Equivalents | 386.75 M | |||
| Cash Per Share | 48.15 X | |||
| Current Ratio | 109.37 X | |||
| Book Value Per Share | 29.55 X | |||
| Cash Flow From Operations | (55.62 M) | |||
| Earnings Per Share | (5.76) X | |||
| Target Price | 300.0 | |||
| Beta | 1.01 | |||
| Market Capitalization | 560.25 M | |||
| Total Asset | 408.48 M | |||
| Net Asset | 408.48 M |
About Infant Bacterial Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infant Bacterial Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infant Bacterial using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infant Bacterial Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.